Administration of a neutralizing anti-CD278 mAb reduced human Treg proportions and numbers and improved CD4+ T cell proliferation therefore highlighting the crucial implication of innate immunity in treatment efficacy, opening new perspectives for the treatment of breast cancer (125). The gene discussed is ICOS; the disease is breast cancer.